Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3413-3422

  Li, Tianhong ^a   Ling, Yi He ^a   Goldman, I David ^a   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; GENES, RAS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34250637524     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2923     Document Type: Article

References (53)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
2. Ardizzoni A,Tiseo M. Second-line chemotherapyi n the treatment of advanced non-small cell lung cancer (NSCLC). J Chemother 2004;16:104-7.
3. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previouslytr eated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
5. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo- 7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4.
6. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23.
7. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17.
8. Zhao R, Goldman ID. Enter Alimta: a new generation antifolate. Oncologist 2004;9:242-4.
9. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
10. Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2004;6:S7-19.
11. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biologya nd treatment of cancer. J Clin Oncol 2003;21:2787-99.
12. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67.
13. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92.
14. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
15. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005;11:3032-7.
16. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking historyto estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006;24:1700-4.
17. Lynch TJ, Adjei AA, Bunn PA, Jr., et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006;12:4365-71s.
18. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
19. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combinationwith erlotinib. J Clin Oncol 2005;23:5900-9.
20. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
21. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101.
22. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
23. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
24. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-6.
25. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. JClin Oncol 2004;22:777-84.
26. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94.
27. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. Proc Am Soc Clin Oncol 2004;23:617A.
28. 2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro [abstract 7028]. Proc Am Soc Clin Oncol 2004;23:620A.
29. Davies AM, Ho C, Lara PN, Jr., et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-8.
30. Piperdi B, Ling Y, Perez-Soler R. Schedule dependent interaction between bortezomib and erlotinib in NSCLC cell lines [abstract 4010]. Proc Amer Assoc Cancer Res 2004;45:927a.
31. Mosmann T. Rapid colorimetric assayf or cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
33. Chou J. Quantitation of synergism and antagonism of two or more drugs bycom puterized analysis. In: ChouT-C, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego: Academic Press; 1991. p. 223-44.
34. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
35. Suzuki T, Nakagawa T, Endo H, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003;42:35-41.
36. Ling YH, Yang Y, Tornos C, et al. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 1998;58:3633-40.
37. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic studyo f OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
38. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations inlung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
39. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every2 1 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80.
40. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I studyof multi-targeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16.
41. Adjei AA. Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res 2006;12:4446-50s.
42. Ling Y-H, Perez-Soler R. Cell cycle effects of the EGFR TK inhibitor erlotinib in NSCLC cell lines [abstract 2284]. Proc Amer Assoc Cancer Res 2005;46:536a.
43. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Am Soc Clin Oncol Annu Meet 2005;23:1.
44. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 2005;23:5856-8.
45. Albain KS, Ravdin PM, Cobau CD, et al. Adjuvant chemohormonal therapyfor primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814) [abstract 143]. Proc Am Soc Clin Oncol 2002;21:37a.
46. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-60.
47. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
48. Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-4.
49. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
50. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activityag ainst epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
51. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60.
52. Wang Y, Zhao R, Goldman ID. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 2004;10:6256-64.
53. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28.